Literature DB >> 34543381

Infection With the US Neisseria meningitidis Urethritis Clade Does Not Lower Future Risk of Urethral Gonorrhea.

Abigail Norris Turner1, Alexandria M Carter1, Yih-Ling Tzeng2, David S Stephens2,3, Morgan A Brown1, Brandon M Snyder1, Adam C Retchless4, Xin Wang4, Jose A Bazan1,5.   

Abstract

BACKGROUND: Cross-protective immunity between Neisseria meningitidis (Nm) and Neisseria gonorrhoeae (Ng) may inform gonococcal vaccine development. Meningococcal serogroup B (MenB) outer membrane vesicle (OMV) vaccines confer modest protection against gonorrhea. However, whether urethral Nm infection protects against gonorrhea is unknown. We examined gonorrhea risk among men with US Nm urethritis clade (US_NmUC) infections.
METHODS: We conducted a retrospective cohort study of men with urethral US_NmUC (n = 128) between January 2015 and April 2018. Using diagnosis date as the baseline visit, we examined Ng status at return visits to compute urethral Ng risk. We compared these data to 3 referent populations: men with urethral Ng (n = 253), urethral chlamydia (Ct) (n = 251), and no urethral Ng or Ct (n = 255). We conducted sensitivity analyses to assess varied approaches to censoring, missing data, and anatomical site of infection. We also compared sequences of protein antigens in the OMV-based MenB-4C vaccine, US_NmUC, and Ng.
RESULTS: Participants were primarily Black (65%) and heterosexual (82%). Over follow-up, 91 men acquired urethral Ng. Men with urethral US_NmUC had similar Ng risk to men with prior urethral Ng (adjusted hazard ratio [aHR]: 1.27; 95% CI: .65-2.48). Men with urethral US_NmUC had nonsignificantly increased Ng risk compared with men with urethral Ct (aHR: 1.51; 95% CI: .79-2.88), and significantly increased Ng risk compared with men without urethral Ng or Ct (aHR: 3.55; 95% CI: 1.27-9.91). Most of the protein antigens analyzed shared high sequence similarity.
CONCLUSIONS: Urethral US_NmUC infection did not protect against gonorrhea despite substantial sequence similarities in shared protein antigens.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 Neisseria gonorrhoeaezzm321990 ; zzm321990 Neisseria meningitidiszzm321990 ; immunity; urethritis; vaccination

Mesh:

Substances:

Year:  2022        PMID: 34543381      PMCID: PMC9258932          DOI: 10.1093/cid/ciab824

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   20.999


  33 in total

1.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

2.  Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero® vaccine.

Authors:  Chiara Tani; Maria Stella; Danilo Donnarumma; Massimiliano Biagini; Pierino Parente; Alessandro Vadi; Claudia Magagnoli; Paolo Costantino; Fabio Rigat; Nathalie Norais
Journal:  Vaccine       Date:  2014-01-23       Impact factor: 3.641

3.  Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.

Authors:  Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil
Journal:  MMWR Recomm Rep       Date:  2020-09-25

4.  Emergence of a new Neisseria meningitidis clonal complex 11 lineage 11.2 clade as an effective urogenital pathogen.

Authors:  Yih-Ling Tzeng; Jose A Bazan; Abigail Norris Turner; Xin Wang; Adam C Retchless; Timothy D Read; Evelyn Toh; David E Nelson; Carlos Del Rio; David S Stephens
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-03       Impact factor: 11.205

5.  Early repeat Chlamydia trachomatis and Neisseria gonorrhoeae infections among heterosexual men.

Authors:  Patricia J Kissinger; Kathleen Reilly; Stephanie N Taylor; Jami S Leichliter; Susan Rosenthal; David H Martin
Journal:  Sex Transm Dis       Date:  2009-08       Impact factor: 2.830

Review 6.  Neisseria gonorrhoeae: Drug Resistance, Mouse Models, and Vaccine Development.

Authors:  Peter A Rice; William M Shafer; Sanjay Ram; Ann E Jerse
Journal:  Annu Rev Microbiol       Date:  2017-09-08       Impact factor: 15.500

Review 7.  Exploitation of Neisseria meningitidis Group B OMV Vaccines Against N. gonorrhoeae to Inform the Development and Deployment of Effective Gonorrhea Vaccines.

Authors:  Helen Petousis-Harris; Fiona J Radcliff
Journal:  Front Immunol       Date:  2019-04-09       Impact factor: 7.561

8.  A meningococcal B vaccine induces cross-protection against gonorrhea.

Authors:  Rolando Felipe Ochoa Azze
Journal:  Clin Exp Vaccine Res       Date:  2019-07-31

Review 9.  Progress Toward a Gonococcal Vaccine: The Way Forward.

Authors:  Michael W Russell; Ann E Jerse; Scott D Gray-Owen
Journal:  Front Immunol       Date:  2019-10-15       Impact factor: 7.561

10.  Biological feasibility and importance of a gonorrhea vaccine for global public health.

Authors:  Leah R Vincent; Ann E Jerse
Journal:  Vaccine       Date:  2018-04-18       Impact factor: 3.641

View more
  1 in total

1.  Meningococcal Carriage in 'Men Having Sex With Men' With Pharyngeal Gonorrhoea.

Authors:  Sara Morselli; Valeria Gaspari; Alessia Cantiani; Melissa Salvo; Claudio Foschi; Tiziana Lazzarotto; Antonella Marangoni
Journal:  Front Cell Infect Microbiol       Date:  2022-01-12       Impact factor: 5.293

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.